Tanida Satoshi, Mizoshita Tsutomu, Nishie Hirotada, Ozeki Keiji, Katano Takahito, Shimura Takaya, Kubota Eiji, Kataoka Hiromi, Kamiya Takeshi, Joh Takashi
Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan; These authors contributed equally to this work.
Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
J Clin Med Res. 2016 Apr;8(4):334-7. doi: 10.14740/jocmr2477w. Epub 2016 Feb 27.
The long-term efficacy and safety of adalimumab (ADA) for the treatment of intestinal Behcet's disease (BD) in the clinical setting have not been evaluated previously. This retrospective study evaluated the 52-week efficacy of ADA in BD patients. A total of eight patients who were refractory to conventional therapy were given ADA (160/80/40 mg every other week). Marked improvement (MI) was achieved by 10 weeks in five patients (62.5%), and by 52 weeks in six patients (75%). In addition, complete remission was obtained in two patients (25%) at both 10 and 52 weeks. Improvement of global gastrointestinal (GI) symptoms to score 0 was observed in three patients (37.5%) at 10 weeks and four patients (50%) at 52 weeks. Moreover, improvement of endoscopic assessment to score 0 was also seen in four patients (50%) at both 10 and 52 weeks. No adverse events were observed in any patients during the 52 weeks. In conclusion, ADA offers an effective, well-tolerated treatment for intestinal BD in patients who are refractory to conventional therapy.
阿达木单抗（ADA）治疗临床环境中肠道白塞病（BD）的长期疗效和安全性此前尚未得到评估。这项回顾性研究评估了ADA对BD患者的52周疗效。共有8例对传统治疗无效的患者接受了ADA治疗（每隔一周160/80/40毫克）。5例患者（62.5%）在10周时实现了显著改善（MI），6例患者（75%）在52周时实现了显著改善。此外，2例患者（25%）在10周和52周时均实现了完全缓解。3例患者（37.5%）在10周时全球胃肠道（GI）症状改善至0分，4例患者（50%）在52周时改善至0分。此外，4例患者（50%）在10周和52周时内镜评估均改善至0分。在52周期间，未观察到任何患者出现不良事件。总之，对于对传统治疗无效的肠道BD患者，ADA提供了一种有效且耐受性良好的治疗方法。
